NCT05182957
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
Clinical trial condition
Relapsed/Refractory Peripheral T-cell Lymphoma
Explore clinical trials studying Relapsed/Refractory Peripheral T-cell Lymphoma. Study availability and eligibility vary by location and protocol.
3 public trials
1 recruiting study
Relapsed/Refractory Peripheral T-cell Lymphoma trial results
NCT05140382
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
- Locations
-
- Research Site Duarte, California, United States
- Research Site Boston, Massachusetts, United States
- Research Site Hackensack, New Jersey, United States
- Research Site Houston, Texas, United States
Active, Not Recruiting
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
NCT04703192
- Conditions
- Adult T Cell Leukemia/Lymphoma, Hematologic Diseases, Hemic and Lymphatic Diseases, +15 more
- Locations
-
- City Of Hope National Medical Center Duarte, California, United States
- Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY Palo Alto, California, United States
- University of California San Francisco San Francisco, California, United States
- University Of Colorado Cancer Center Aurora, Colorado, United States